Which has better valuation and earnings, VRPX or SCPS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is VRPX or SCPS more profitable?

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Scopus BioPharma N/A N/A N/A

Is VRPX or NAVB more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Navidea Biopharmaceuticals N/A N/A N/A

Is GNCA or VRPX more profitable?

Genocea Biosciences' return on equity of -182.88% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Which has stronger earnings and valuation, PXMD or VRPX?

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A

Is PXMD or VRPX more profitable?

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Which has preferable valuation & earnings, VRPX or ARDS?

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 0.00

Is VRPX or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Aridis Pharmaceuticals N/A N/A N/A

Virpax Pharmaceuticals (VRPX) Competitors

$0.01 0.00 (0.00%)

As of 07/10/2026 03:48 PM Eastern

Compare

VRPX vs. SCPS, NAVB, GNCA, PXMD, and ARDS

Should you buy Virpax Pharmaceuticals stock or one of its competitors? MarketBeat compares Virpax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virpax Pharmaceuticals include Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), and Aridis Pharmaceuticals (ARDS). These companies are all part of the "pharmaceutical products" industry.

How does Virpax Pharmaceuticals compare to Scopus BioPharma?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Scopus BioPharma	N/A	N/A	N/A

Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Scopus BioPharma	Neutral

Summary

Scopus BioPharma beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Navidea Biopharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Navidea Biopharmaceuticals	N/A	N/A	N/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Navidea Biopharmaceuticals	Neutral

Navidea Biopharmaceuticals has higher revenue and earnings than Virpax Pharmaceuticals. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Virpax Pharmaceuticals has a beta of -16.52, suggesting that its share price is 1,752% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Virpax Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Genocea Biosciences' return on equity of -182.88% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Virpax Pharmaceuticals	Neutral

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virpax Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

Summary

Genocea Biosciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PaxMedica is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, suggesting that its share price is 1,752% less volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Virpax Pharmaceuticals	Neutral

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Summary

Virpax Pharmaceuticals beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Aridis Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Aridis Pharmaceuticals	N/A	N/A	N/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Aridis Pharmaceuticals	Neutral

Virpax Pharmaceuticals has a beta of -16.52, indicating that its stock price is 1,752% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, indicating that its stock price is 4,659% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Virpax Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRPX vs. The Competition

Export

Metric	Virpax Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14K	$971.70M	$7.14B	$12.64B
Dividend Yield	N/A	4.84%	2.68%	7.83%
P/E Ratio	0.00	1.64	27.42	24.58
Price / Sales	N/A	117.18	593.42	121.59
Price / Cash	N/A	20.06	49.34	60.04
Price / Book	0.01	8.46	10.88	6.38
Net Income	-$15.19M	-$2.88M	$3.59B	$331.87M
7 Day Performance	N/A	-0.89%	-0.26%	0.37%
1 Month Performance	N/A	2.83%	4.52%	0.53%
1 Year Performance	N/A	43.51%	29.17%	21.96%

Virpax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-96.6%	$14K	N/A	N/A	7	Gap Up
SCPS Scopus BioPharma	N/A	$0.00 -16.7%	N/A	N/A	$21K	N/A	N/A	9	High Trading Volume
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	+600.0%	$6K	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virpax Pharmaceuticals (VRPX) Competitors

VRPX vs. SCPS, NAVB, GNCA, PXMD, and ARDS

How does Virpax Pharmaceuticals compare to Scopus BioPharma?

Summary

How does Virpax Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Virpax Pharmaceuticals compare to Genocea Biosciences?

Summary

How does Virpax Pharmaceuticals compare to PaxMedica?

Summary

How does Virpax Pharmaceuticals compare to Aridis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRPX vs. The Competition

Virpax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virpax Pharmaceuticals (VRPX) Competitors

VRPX vs. SCPS, NAVB, GNCA, PXMD, and ARDS

How does Virpax Pharmaceuticals compare to Scopus BioPharma?

Do insiders and institutionals hold more shares of VRPX or SCPS?

Is VRPX or SCPS more profitable?

Which has more risk and volatility, VRPX or SCPS?

Which has better valuation and earnings, VRPX or SCPS?

Does the media refer more to VRPX or SCPS?

Summary

How does Virpax Pharmaceuticals compare to Navidea Biopharmaceuticals?

Is VRPX or NAVB more profitable?

Do insiders and institutionals hold more shares of VRPX or NAVB?

Does the media prefer VRPX or NAVB?

Which has preferable valuation & earnings, VRPX or NAVB?

Which has more volatility and risk, VRPX or NAVB?

Summary

How does Virpax Pharmaceuticals compare to Genocea Biosciences?

Is GNCA or VRPX more profitable?

Does the media prefer GNCA or VRPX?

Which has more volatility & risk, GNCA or VRPX?

Do institutionals & insiders hold more shares of GNCA or VRPX?

Which has better earnings and valuation, GNCA or VRPX?

Summary

How does Virpax Pharmaceuticals compare to PaxMedica?

Do insiders & institutionals believe in PXMD or VRPX?

Which has stronger earnings and valuation, PXMD or VRPX?

Which has more risk & volatility, PXMD or VRPX?

Does the media refer more to PXMD or VRPX?

Is PXMD or VRPX more profitable?

Summary

How does Virpax Pharmaceuticals compare to Aridis Pharmaceuticals?

Is VRPX or ARDS more profitable?

Do insiders and institutionals hold more shares of VRPX or ARDS?

Which has preferable valuation & earnings, VRPX or ARDS?

Does the media refer more to VRPX or ARDS?

Which has more volatility & risk, VRPX or ARDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRPX vs. The Competition

Virpax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools